$1.665
Live
Insights on Cytomx Therapeutics Inc
Revenue is up for the last 5 quarters, 946.0K → 26.60M (in $), with an average increase of 27.0% per quarter
Netprofit is down for the last 2 quarters, 2.99M → 837.0K (in $), with an average decrease of 72.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 47.8%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 329.1%
0.3%
Downside
Day's Volatility :2.06%
Upside
1.76%
37.72%
Downside
52 Weeks Volatility :63.64%
Upside
41.61%
Period | Cytomx Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 9.8% | 1.9% | 0.0% |
6 Months | 32.28% | 10.7% | 0.0% |
1 Year | 3.07% | 4.6% | -1.1% |
3 Years | -82.3% | 14.2% | -22.1% |
Market Capitalization | 113.1M |
Book Value | - $0.7 |
Earnings Per Share (EPS) | -0.01 |
PEG Ratio | -1.8 |
Wall Street Target Price | 2.9 |
Profit Margin | -0.56% |
Operating Margin TTM | -2.28% |
Return On Assets TTM | -1.75% |
Return On Equity TTM | -5475.03% |
Revenue TTM | 101.2M |
Revenue Per Share TTM | 1.37 |
Quarterly Revenue Growth YOY | 32.2% |
Gross Profit TTM | 53.2M |
EBITDA | -4.3M |
Diluted Eps TTM | -0.01 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.19 |
EPS Estimate Next Year | -0.37 |
EPS Estimate Current Quarter | -0.03 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 74.17%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 59.5M | ↓ 16.92% |
Net Income | -84.6M | ↑ 96.3% |
Net Profit Margin | -142.19% | ↓ 82.02% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 57.5M | ↓ 3.38% |
Net Income | -102.2M | ↑ 20.84% |
Net Profit Margin | -177.84% | ↓ 35.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 100.4M | ↑ 74.58% |
Net Income | -32.9M | ↓ 67.83% |
Net Profit Margin | -32.77% | ↑ 145.07% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 69.6M | ↓ 30.68% |
Net Income | -80.6M | ↑ 145.24% |
Net Profit Margin | -115.92% | ↓ 83.15% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 53.2M | ↓ 23.59% |
Net Income | -97.3M | ↑ 20.65% |
Net Profit Margin | -183.02% | ↓ 67.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 101.2M | ↑ 90.38% |
Net Income | -569.0K | ↓ 99.42% |
Net Profit Margin | -0.56% | ↑ 182.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 16.9M | ↓ 6.88% |
Net Income | -22.7M | ↓ 4.13% |
Net Profit Margin | -133.9% | ↓ 3.84% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 946.0K | ↓ 94.41% |
Net Income | -26.6M | ↑ 17.35% |
Net Profit Margin | -2.8K% | ↓ 2675.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.5M | ↑ 2384.04% |
Net Income | -969.0K | ↓ 96.35% |
Net Profit Margin | -4.12% | ↑ 2805.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.7M | ↑ 5.21% |
Net Income | -1.1M | ↑ 12.18% |
Net Profit Margin | -4.4% | ↓ 0.28% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 26.4M | ↑ 6.71% |
Net Income | 3.0M | ↓ 375.25% |
Net Profit Margin | 11.34% | ↑ 15.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 26.6M | ↑ 0.85% |
Net Income | 837.0K | ↓ 72.03% |
Net Profit Margin | 3.15% | ↓ 8.19% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 457.1M | ↑ 14.95% |
Total Liabilities | 326.2M | ↓ 0.46% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 341.3M | ↓ 25.34% |
Total Liabilities | 290.2M | ↓ 11.05% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 358.7M | ↑ 5.09% |
Total Liabilities | 308.9M | ↑ 6.44% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 339.4M | ↓ 5.37% |
Total Liabilities | 250.0M | ↓ 19.05% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 260.9M | ↓ 23.13% |
Total Liabilities | 346.6M | ↑ 38.64% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 205.2M | ↓ 21.37% |
Total Liabilities | 252.6M | ↓ 27.13% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 226.5M | ↓ 12.92% |
Total Liabilities | 198.0M | ↓ 6.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 260.9M | ↑ 15.19% |
Total Liabilities | 346.6M | ↑ 75.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 234.6M | ↓ 10.07% |
Total Liabilities | 321.3M | ↓ 7.32% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 209.2M | ↓ 10.84% |
Total Liabilities | 294.2M | ↓ 8.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 221.2M | ↑ 5.73% |
Total Liabilities | 272.4M | ↓ 7.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 205.2M | ↓ 7.24% |
Total Liabilities | 252.6M | ↓ 7.27% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -75.5M | ↓ 144.33% |
Investing Cash Flow | 5.9M | ↓ 104.89% |
Financing Cash Flow | 139.6M | ↑ 486.75% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -140.5M | ↑ 86.01% |
Investing Cash Flow | 79.7M | ↑ 1244.94% |
Financing Cash Flow | 1.6M | ↓ 98.83% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.3M | ↓ 103.74% |
Investing Cash Flow | -18.7M | ↓ 123.49% |
Financing Cash Flow | 16.9M | ↑ 938.29% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -119.0M | ↓ 2363.38% |
Investing Cash Flow | 22.5M | ↓ 220.15% |
Financing Cash Flow | 110.2M | ↑ 552.42% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -110.8M | ↓ 6.93% |
Investing Cash Flow | 22.5M | ↑ 0.0% |
Financing Cash Flow | 648.0K | ↓ 99.41% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -33.8M | ↓ 1.15% |
Investing Cash Flow | -410.0K | ↓ 0.49% |
Financing Cash Flow | 458.0K | ↑ 1.55% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.4M | ↓ 95.88% |
Investing Cash Flow | -245.0K | ↓ 40.24% |
Financing Cash Flow | 190.0K | ↓ 58.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.3M | ↓ 770.66% |
Investing Cash Flow | -146.6M | ↑ 59753.88% |
Financing Cash Flow | 317.0K | ↑ 66.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↓ 369.31% |
Investing Cash Flow | 26.0M | ↓ 117.76% |
Financing Cash Flow | 317.0K | ↑ 0.0% |
Sell
Neutral
Buy
Cytomx Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cytomx Therapeutics Inc | -21.5% | 32.28% | 3.07% | -82.3% | -83.17% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cytomx Therapeutics Inc | NA | NA | -1.8 | -0.19 | -54.75 | -0.02 | NA | -0.7 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cytomx Therapeutics Inc | Hold | $113.1M | -83.17% | NA | -0.56% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Bvf Inc
TANG CAPITAL MANAGEMENT LLC
Vanguard Group Inc
Acadian Asset Management LLC
Renaissance Technologies Corp
LAURION CAPITAL MANAGEMENT LP
Cytomx Therapeutics Inc’s price-to-earnings ratio stands at None
Read Morecytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
Organization | Cytomx Therapeutics Inc |
Employees | 120 |
CEO | Dr. Sean A. McCarthy DPHIL |
Industry | Health Technology |